Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01843855 · ClinicalTrials.gov registry record · Early Phase 1
The Contribution of Incretin Hormones to the Amelioration of Glucose Metabolism After Roux-en-Y Gastric Bypass
A Early Phase 1 study, sponsored by Adrian Vella.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 12
- Enrollment target
NCT01843855 is a Early Phase 1 study that has completed, run by Adrian Vella. The registered enrollment target is 12 participants.
The verdict
NCT01843855, a Early Phase 1 study, has completed, sponsored by Adrian Vella.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The study is being undertaken to understand how a gastric bypass can affect a subject's diabetes even prior to their losing significant amounts of weight. The hypothesis of this study is that increased glucagon-like peptide-1 (GLP-1) secretion explains the amelioration in insulin secretion after Roux-en-Y Gastric Bypass (RYGB) surgery.
Interventions
- DRUG Placebo
- DRUG Exendin 9,39
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2011-06 |
| Est. Completion | 2013-09 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01843855
The ClinicalTrials.gov registry entry for NCT01843855 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Adrian Vella, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01843855 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01843855 about?
NCT01843855 is a clinical study titled "The Contribution of Incretin Hormones to the Amelioration of Glucose Metabolism After Roux-en-Y Gastric Bypass". The study is being undertaken to understand how a gastric bypass can affect a subject's diabetes even prior to their losing significant amounts of weight. The hypothesis of this study is that increased glucagon-like peptide-1 (GLP-1) secretion explains the amelioration in insulin secretion after Rou...
What is the current status of trial NCT01843855?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 12 participants. The study started on 2011-06. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01843855?
The interventions under investigation include: Placebo (DRUG), Exendin 9,39 (DRUG).
Who is sponsoring clinical trial NCT01843855?
This trial is sponsored by Adrian Vella, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.